Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors

Por E. V. Artamonova, E. I. Kovalenko
Publicado em 2019-09-01

Efficiency and tolerability of abemaciclib in elderly patients

Por E. I. Kovalenko, M. V. Khoroshilov, E. V. Artamonova
Publicado em 2020-12-01

Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy f...

Por I. B. Kononenko, A. V. Snegovoi, L. V. Manzyuk, E. I. Kovalenko, V. Yu. Selchuk
Publicado em 2018-11-01

Adverse effects of adjuvant endocrine therapy

Por E. I. Kovalenko, I. B. Kononenko, A. V. Snegovoi, O. P. Grebennikova, L. V. Manzyuk
Publicado em 2018-07-01

Importance of evaluation of ovarian function in women with breast cancer when using endocrinotherapy

Por I. B. Kononenko, A. V. Snegovoi, E. I. Kovalenko, L. V. Manzyuk, V. Yu. Selchuk
Publicado em 2018-07-01

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’...

Por E. V. Artamonova, E. I. Kovalenko, L. V. Bolotina, M. B. Stenina, R. V. Orlova, M. A. Mukhina
Publicado em 2021-01-01

DISTRIBUTION OF <i>MICA</i> ALLELES IN THE RUSSIAN POPULATION

Por L. M. Kanevskiy, M. V. Grechikhina, E. G. Kuzmina, T. Yu. Mushkarina, A. A. Spelkov, M. A. Streltsova, E. I. Kovalenko
Publicado em 2019-12-01

CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS

Por A. V. Klinkova, E. G. Kuzmina, E. V. Abakushina, L. M. Kanevskiy, G. S. Neprina, V. V. Pavlov, E. I. Kovalenko
Publicado em 2016-04-01

Analysis of the association of the polymorphism of the CLIC1, MSH5, C6orf26, C6orf25 genes with the expression level of the HSPA1B gene

Por Yu. D. Vavilovа, A. A. Boyko, E. I. Kovalenko, M. V. Grechikhina, O. A. Shustova, T. L. Azhikina, A. M. Sapozhnikov
Publicado em 2020-08-01

Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review)

Por Yu. S. Krumin, V. A. Khaylenko, N. A. Kozlov, G. Yu. Cheremis, A. V. Petrovskyy, D. V. Khaylenko, E. V. Artamonova, E. I. Kovalenko
Publicado em 2021-03-01

TREATMENT OF BREAST CANCER WITH METASTATIC CONTRALATERAL AXILLARY LYMPH NODES: CASE REPORT AND LITERATURE REVIEW

Por V. A. Amosova, A. V. Petrovsky, M. V. Chernykh, E. I. Kovalenko, M. A. Frolova, R. K. Valiev, M. I. Nechushkin, V. U. Kirsanov, I. V. Vysotskaya, D. E. Avtomonov
Publicado em 2020-01-01

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study

Por L.  A. Tashireva, N. O. Popova, V. V. Alifanov, V. E.  Goldberg, E. I. Kovalenko, E. V. Artamonova, A. G.  Manikhas, D. M. Ponomarenko, N. V. Levchenko, E. I. Rossokha, S. Yu.  Krasilnikova, M. A. Zafirova, V. M.  Perelmuter
Publicado em 2022-01-01

Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian pati...

Por E V Artamonova, E I Kovalenko, A V Snegovoy, A A Aksarin, T A Anciferova, A V Belonogov, E V Bilan, S N Bilenko, I M Varvus, E A Gorkovenko, R F Enikeev, A M Ermolaeva, L V Kramskaya, I B Kononenko, A P Pechenyy, S Z Safina, T V Chupriyanova, G G Chuhua, A I Shemyakina, E V Shikina
Publicado em 2018-09-01

The improvement in overall survival for patients with metastatic breast cancer treated with eribulin: the resolution based on results of the expert council

Por V S Andrianova, A V Beliaeva, L V Bolotina, A A Vazhenina, S E Varlamova, V I Vladimirov, L Yu Vladimirova, E K Voznyi, S M Demidov, N V Zhukov, L G Zhukova, E N Imianitov, E I Kovalenko, L M Kogoniia, M M Konstantinova, S A Lan, M R Lichinitser, L V Manziuk, A G Manikhas, G Z Mukhametshina, V F Semiglazov, T Iu Semiglazova, G V Seregina, D L Stroiakovskii, M D Ter-Ovanesov, A S Chichkanova
Publicado em 2015-03-01

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study

Por E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Publicado em 2021-12-01